Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Connect Biopharma Holdings Limited Sponsored ADR (CNTB : NSDQ)
 
 • Company Description   
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients living with chronic inflammatory diseases through the development of therapies derived from our T cell-driven research. The company's product candidate includes CBP-201. Connect Biopharma Holdings Limited is based in TAICANG, China.

Number of Employees: 62

 
 • Price / Volume Information   
Yesterday's Closing Price: $18.48 Daily Weekly Monthly
20 Day Moving Average: 59,751 shares
Shares Outstanding: 57.50 (millions)
Market Capitalization: $1,062.68 (millions)
Beta:
52 Week High: $23.29
52 Week Low: $14.02
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 23.20% 21.87%
12 Week -0.11% -6.44%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
East R&D Building 3rd Floor Science and Technology Park 6 Beijing West Road
-
TAICANG,F4 215400
CHN
ph: 86-512-5357-7866
fax: -
david.carey@finnpartners.com http://www.connectbiopharm.com
 
 • General Corporate Information   
Officers
William Pan - Chief Executive Officer & Director
William Pan - Chairman of Directors & President
Selwyn HoMBBS - Chief Operating Officer
Eric J. Hall - Chief Financial Officer
Lei Sun - Vice President

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 207523101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding: 57.50
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $1,062.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.36 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.19 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/21 - -
12/31/20 - -
09/30/20 - -
ROA
03/31/21 - -
12/31/20 - -
09/30/20 - -
Current Ratio
03/31/21 - -
12/31/20 - 27.81
09/30/20 - -
Quick Ratio
03/31/21 - -
12/31/20 - 27.81
09/30/20 - -
Operating Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Net Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Pre-Tax Margin
03/31/21 - -
12/31/20 - -
09/30/20 - -
Book Value
03/31/21 - -
12/31/20 - -
09/30/20 - -
Inventory Turnover
03/31/21 - -
12/31/20 - -
09/30/20 - -
Debt-to-Equity
03/31/21 - -
12/31/20 - -
09/30/20 - -
Debt-to-Capital
03/31/21 - -
12/31/20 - -
09/30/20 - -
 

Powered by Zacks Investment Research ©